Can't wait to see the results. Efficacy across several patients would be amazing but happy as long as no signs of dose limiting toxicities are present.
Also, not sure if its a typo or when the plan was changed (probably an older figure), on Chimerics website under pipeline, the CHM 1101 dosing schema states 220 x 10^6 as the third dose, rather than 240 x 10^6 described here and in the annual report.
Anyone have any idea when they increased the dosage of the third cohort or if its just a type?
Can't wait to see the results. Efficacy across several patients...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
0.002(11.1%) |
Mkt cap ! $17.25M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 2.0¢ | 1.9¢ | $26.18K | 1.372M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 736556 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1462067 | 5 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CHM (ASX) Chart |